

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 10, 2018

NxSTAGE MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation)

000-51567
(Commission File Number)

04-3454702
(I.R.S. Employer Identification No.)

350 Merrimack Street, Lawrence, MA
(Address of principal executive offices)

01843
(Zip Code)

(978) 687-4700
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01 Other Events

On July 10, 2018, NxStage Medical, Inc. ("NxStage") agreed to sell its bloodlines business operated under the Medisystems name to B. Braun Medical Inc. Consummation of the transaction is subject to (1) the Federal Trade Commission's ("FTC") approval of the transaction, (2) the closing of the pending merger of NxStage with a subsidiary of Fresenius Medical Care Holdings, Inc. ("Fresenius Merger") and (3) other customary conditions. The divestiture agreement was entered into with the goal of advancing the process to obtain FTC clearance of the pending Fresenius Merger under the Hart-Scott-Rodino Act. NxStage continues to expect the Fresenius Merger to close in 2018.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NxStage Medical, Inc.

By: /s/ Winifred L. Swan
Winifred L. Swan
General Counsel

Date: July 18, 2018